GH: Guardant Health, Inc.
About
Guardant Health, Inc. is a precision oncology company engaged in the treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H. Talasaz, and Michael Joseph Wiley in 2011 and is headquartered in Palo Alto, CA.
Current Value
$30.661 Year Return
Current Value
$30.661 Year Return
Key Details
Market Cap
$3.79B
P/E Ratio
-7.24
1Y Stock Return
33.86%
1Y Revenue Growth
29.20%
Dividend Yield
0.00%
Price to Book
-62.9
Strategies that include GH
Stock's related to GH
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| VCYT | 48.91% | $3.03B | +55.48% | 0.00% |
| NVCR | 42.11% | $1.78B | +34.75% | 0.00% |
| ARHS | 41.48% | $1.30B | +6.48% | 0.00% |
| BIGC | 41.37% | $473.42M | -31.75% | 0.00% |
| VAC | 40.84% | $3.13B | +16.15% | 3.39% |
| DLX | 40.06% | $1.01B | +24.44% | 5.30% |
| BATRK | 39.83% | $2.51B | +13.03% | 0.00% |
| BURL | 39.76% | $17.44B | +66.00% | 0.00% |
| HAE | 39.64% | $4.26B | +2.89% | 0.00% |
| BLFS | 39.47% | $1.04B | +64.64% | 0.00% |
| KAR | 39.38% | $2.09B | +31.90% | 0.00% |
| AMRC | 39.17% | $1.39B | -4.40% | 0.00% |
| BRKL | 38.91% | $1.08B | +30.28% | 4.48% |
| MGNI | 38.78% | $2.29B | +105.56% | 0.00% |
| YORW | 38.13% | $514.17M | -3.87% | 2.37% |
| QGEN | 38.07% | $9.05B | -1.92% | 0.00% |
| PLYM | 38.07% | $842.88M | -11.32% | 5.12% |
| NTB | 37.94% | - | - | 4.69% |
| FOXF | 37.90% | $1.33B | -47.63% | 0.00% |
| ORGO | 37.89% | $540.91M | +59.38% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CAH | -0.01% | $28.64B | +12.14% | 1.70% |
| GALT | 0.03% | $172.91M | +41.28% | 0.00% |
| LPLA | 0.10% | $23.55B | +38.13% | 0.38% |
| WRAP | -0.10% | $62.86M | -49.45% | 0.00% |
| GYRE | -0.10% | $1.21B | +1.49% | 0.00% |
| QXO | 0.12% | $6.51B | -35.95% | 0.00% |
| NFLX | 0.13% | $372.45B | +83.46% | 0.00% |
| MVO | 0.16% | $106.15M | -22.78% | 16.78% |
| MSDL | 0.18% | $1.83B | +0.66% | 7.26% |
| SNY | 0.19% | $120.34B | +3.11% | 4.25% |
| KLG | -0.20% | $1.48B | +45.15% | 3.71% |
| BACK | 0.22% | $1.76M | -32.90% | 0.00% |
| NHTC | -0.23% | $61.83M | +0.19% | 14.81% |
| MSB | -0.24% | $337.71M | +30.73% | 5.15% |
| MNR | -0.24% | $1.66B | -10.71% | 15.90% |
| ACRS | -0.26% | $327.87M | +415.67% | 0.00% |
| TSN | 0.29% | $21.95B | +31.14% | 3.11% |
| NTIC | -0.32% | $132.27M | +24.98% | 2.02% |
| HRTG | -0.35% | $371.89M | +58.22% | 0.00% |
| NTNX | 0.38% | $18.33B | +70.72% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| PGR | -12.19% | $149.10B | +57.29% | 0.45% |
| HUSA | -12.02% | $16.69M | -11.56% | 0.00% |
| COLL | -11.86% | $959.44M | +16.71% | 0.00% |
| GAN | -10.93% | $83.39M | +21.19% | 0.00% |
| STG | -10.73% | $35.67M | +7.92% | 0.00% |
| BNED | -10.47% | $277.22M | -91.94% | 0.00% |
| SOLV | -10.41% | $11.58B | -16.19% | 0.00% |
| ACGL | -9.12% | $36.00B | +16.84% | 0.00% |
| LLY | -9.12% | $692.74B | +23.14% | 0.71% |
| LQDA | -8.82% | $859.91M | +53.94% | 0.00% |
| FAT | -7.60% | $89.30M | -11.53% | 10.73% |
| CME | -7.24% | $82.76B | +9.21% | 1.98% |
| FATBB | -7.09% | $81.94M | -12.91% | 11.69% |
| COR | -6.81% | $47.48B | +21.20% | 0.86% |
| GLP | -6.77% | $1.77B | +51.33% | 5.50% |
| KRRO | -6.40% | $436.84M | +20.68% | 0.00% |
| LMT | -6.25% | $126.40B | +18.99% | 2.36% |
| CYCN | -6.15% | $4.77M | -16.19% | 0.00% |
| ALAB | -6.09% | $15.10B | +164.39% | 0.00% |
| VHC | -5.38% | $19.06M | -38.36% | 0.00% |
ETF's related to GH
News
Yahoo
On Wednesday, Guardant Health stock got a positive adjustment to its Relative Strength (RS) Rating, from 75 to 83. This exclusive rating from Investor's Business Daily measures price action with a 1 (worst) to 99 (best) score.
SeekingAlpha
Guardant Health's heavy investment in R&D, growing from $10.9 million in 2016 to $365.1 million in 2023, indicates a focus on future growth. Learn more on GH stock here.
SeekingAlpha
Following underperformance in Q2 2024, the Franklin Biotechnology Discovery Fund returned to strength in Q3 2024. Click here to read the full commentary.
Yahoo
PALO ALTO, Calif., November 13, 2024--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on October 22, 2024, the Compensation Committee of Guardant’s Board of Directors approved the granting of restricted stock units ("RSUs") representing 233,603 shares of its common stock to 123 new non-executive employees and non-qualified stock option awards to purchase an aggregate of 50,349 shares of its common stock to three new non-executive employees with a gr
Yahoo
The rock star money manager is starting to roll with the rallying market.
Yahoo
Guardant Health ( NASDAQ:GH ) Third Quarter 2024 Results Key Financial Results Revenue: US$191.5m (up 34% from 3Q...
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.